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Abstract 31 
The gastrointestinal (GI) tract is one of the most popular and used routes of drug product 32 
administration due to the convenience for better patient compliance and reduced costs to the patient 33 
compared to other routes. However, its complex nature poses a great challenge for formulation scientists 34 
when developing more complex dosage forms such as those combining two or more drugs. Fix dosed 35 
combination (FDC) products are two or more single active ingredients combined in a single dosage form. 36 
This formulation strategy represents a novel formulation which is as safe and effective compared to every 37 
mono-product separately. A complex drug product, to be dosed through a complex route, requires judicious 38 
considerations for formulation development. Additionally, it represents a challenge from a regulatory 39 
perspective at the time of demonstrating bioequivalence (BE) for generic versions of such drug products. 40 
This report gives the reader a summary of a two-day short course that took place on the third and fourth of 41 
November at the annual association of pharmaceutical scientists (AAPS) meeting in 2018 at Washington, 42 
D.C. This manuscript will offer a comprehensive view of the most influential aspects of the GI physiology 43 
on the absorption of drugs and current techniques to help understand the fate of orally ingested drug 44 
products in the complex environment represented by the GI tract. Through case studies on FDC product 45 
development and regulatory issues, this manuscript will provide a great opportunity for readers to explore 46 
avenues for successfully developing FDC products and their generic versions.  47 
From Stomach to Large Intestine: A Thorough Review of Gastrointestinal Physiology – Maura 48 
Corsetti, MD, PhD and Bart Hens, PharmD, PhD 49 
From an anatomical point of view, the stomach is divided into a fundus, corpus (i.e.,body) and 50 
antrum region, but when it comes to motor function two parts can be distinguished: the proximal stomach, 51 
consisting of the fundus and the proximal part of the corpus, and the distal stomach consisting of the distal 52 
part of the corpus and the antrum. The motility of the proximal stomach is characterized by a maintained 53 
status of contractions of the smooth muscle (tone), whereas the distal stomach generates phasic 54 
contractions. During the interdigestive phase, the proximal stomach muscle tone is high, whereas the distal 55 
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stomach is engaged in a recurrent motor pattern known as the migrating motor complex (MMC) [1]. This 56 
complex involves the stomach and the majority of the small bowel (but not the distal small bowel) with 57 
three phases: phase I, a quiescent phase with no contractions; phase II with until recently considered random 58 
contractions; phase III with a sudden onset of repetitive contractions that also ends abruptly. The phase III 59 
can start in the stomach or in the proximal small intestine and then migrate towards the distal ileum. Gastric 60 
pH fluctuates during the MMC, with the antral pH being lowest (more acidic) just prior to the start of phase 61 
III contractions, and higher at the start of phase I. This change in pH is due to an increase in acid and pepsin 62 
secretion that accompanies phase III of the MMC, and bile-free, bicarbonate reflux from the duodenum. 63 
Intestinal and pancreatic secretions (e.g., water, bicarbonate and pancreatic enzymes) increase during phase 64 
III contractions of the small intestine [2,3]. As soon as the food is ingested, the proximal stomach will relax 65 
to accommodate the food, followed by a tonic contraction of the proximal stomach which will push the 66 
food more distally. The distal stomach will mix and grind the food by powerful and regular contractions. 67 
The duodenum is exposed to nutrients almost directly after the ingestion of food and this will activate a 68 
multitude of duodeno-gastric negative-feedback mechanisms, as for instance mediated through vagal 69 
reflexes and hormonal signals. This will delay the arrival of acidic, hyperosmotic, or calorie-rich gastric 70 
contents into the duodenum by inhibiting proximal gastric tone, and phasic contractions, stimulating the 71 
closure of the pylorus [4]. The physical consistency, fat content and caloric load of the meal play a relevant 72 
role in regulating the motor response of the stomach. Liquids of low caloric density empty under the 73 
pressure gradient created by the fundus tone and the little motor action of the distal stomach in an 74 
exponential fashion. Digestible food of more solid consistency requires antral trituration until the particle 75 
size is reduced [5]. The time that the stomach takes to reduce the particles may explain the lag phase 76 
observed before emptying can start. Thus, gastric emptying occurs in two periods: the lag period 77 
(responsible for digestion of solid material) and the post-lag, linear emptying period when digested solid 78 
particles or liquids can easily be emptied from the stomach. Non-digestible solids are usually emptied from 79 
the stomach with the inter-digestive phase III of MMC [5]. A recent study demonstrated the impact of these 80 
phase III contractions to clear ibuprofen from the stomach into the small intestine [6]. These contractions 81 
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in combination with the pH played a pivotal role in the onset of intestinal absorption, determining the 82 
plasma Cmax and Tmax. A clinical aspiration study was recently performed to investigate the gastric emptying 83 
rate of a glass of water in fasted and fed state conditions [7]. A standardized dose of phenol red was added 84 
to the glass of water and ingested by healthy subjects. After drinking the glass of water, gastrointestinal 85 
(GI) fluids were aspirated from the stomach, duodenum and jejunum. Based on computational modeling, 86 
authors identified that gastric emptying of a glass of water is tremendously rapid, especially in fasted state, 87 
and will be triggered by the present motility at the time of water administration [7–9]. Scintigraphy is 88 
considered the gold standard to study gastric emptying in humans, and this is normally defined by the 89 
percentage of gastric retention at 1 h, 2 h and at 4 h. However, the use of a single summary outcome 90 
measurement does not allow to capture the above-reported complex mechanisms activated by a meal [10]. 91 
Nottingham has published the normal values of a gastric emptying test based on a liquid meal, as described 92 
by Parker and co-workers, to obtain a comprehensive assessment of gastric motor and sensory function. 93 
This test allows differentiating an early and a late phase of gastric emptying for a liquid meal that may 94 
reflect the gastric accommodation and the antral component of the gastric emptying [10,11]. Recently, two 95 
techniques have been developed to study the gastric function. The SmartPill® is an ingestible device (26 96 
mm by 13 mm) measures intraluminal pH, pressure and temperature. It wirelessly transmits data to a 97 
wearable external recorder, allowing ambulatory studies at home [12,13]. The variations in luminal pH, as 98 
well as the drop in temperature after defecation, allows accurate measurement of regional as well as whole 99 
gut transit times. However, it should be noted that in consideration of the dimension of the device does not 100 
reflect the gastric emptying of normal digestible food and indeed the gastric emptying has been found to be 101 
longer than that measured by scintigraphy [13]. In any case, this technique has the advantage of being non-102 
invasive and of combining the measurement of pH and of the whole gut transit time. Besides telemetric 103 
capsules, magnetic resonance imaging (MRI) has been recently applied to the study the GI function and 104 
this technique offers some major advantages compared to other techniques: it is non-invasive, does not 105 
expose subjects to ionizing radiation, and does not require any contrast medium. It is a unique technique 106 
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that offers the possibility of simultaneously measuring gastric, small intestinal and colonic volumes, the 107 
physicochemical characteristics of the luminal environment, transit rate and to quantify motility [14]. This 108 
technique has not yet been standardized across research centers and for the moment does not allow the 109 
evaluation of gastric function in an upright position [15].  In summary, the human stomach is more complex 110 
as it seems and can play a major role in further intraluminal drug behavior along the intestinal tract where 111 
absorption takes place. 112 
Beyond the stomach, the intraluminal processes in the small intestine will play a pivotal role with 113 
respect to drug absorption. In this second talk, there was a specific focus on (i) the residual intestinal fluid 114 
volumes, (ii) the characterization and composition of the intestinal fluids and (iii) the permeability of the 115 
intestinal wall for drug compounds. The residual fluid volumes in the intestinal tract are rather scarce and 116 
not homogenously distributed as a pool of water from the proximal towards the distal part. Distribution of 117 
these fluids is organized in different fluid pockets [9,16]. The variability in the number of pockets and the 118 
actual volume for each pocket is tremendously high between healthy subjects, as highlighted by Mudie and 119 
co-workers [9]. This finding was an important investigation for formulation scientists to be aware of the 120 
fact that the intestinal tract is not like a ‘swimming pool’, completely filled with water. The prediction of 121 
the in vivo performance of orally administered drug products has shown to be more accurate when applying 122 
the fluid dynamics as observed by Mudie et al. instead of using static and high volumes. This was observed 123 
for posaconazole, a weakly basic compound, for which the in vivo performance was predicted by using a 124 
dynamic fluid and pH model in simulation software [17]. Although this model shows to have an impact on 125 
predicting the in vivo performance for compounds suffering from a poorly aqueous solubility, authors 126 
concluded that this model may not have an immense impact on the predicted systemic exposure for 127 
compounds characterized by a high solubility. Moreover, as mentioned before, there is huge intersubject 128 
variability in the number and volume of pockets. For instance, one subject showed to have only 2 pockets 129 
with a total volume of 1.4 mL whereas another subject demonstrated to have 23 pockets with a total volume 130 
of 160 mL. A follow-up study aims to unravel a potential link between the appearance of fluid pockets and 131 
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the present motility [14]. In the seventies, Vantrappen et al. observed a higher secretion rate of bicarbonate 132 
shortly after an upper GI phase III contraction [3]. In doing so, the gastric acid of the stomach entering the 133 
small intestine could directly be neutralized by the bicarbonate buffer. This so-called ‘secretomotor 134 
complex’ is highly likely to be a responsible factor in the formation of water pockets inside the intestinal 135 
tract.  Besides gaining knowledge with respect to the present volumes in the GI tract, the composition of 136 
these fluids is another important aspect. In a recent study, human duodenal fluids were aspirated from 20 137 
healthy subjects in the fasted and fed state [18]. The fed state was simulated by ingestion of a liquid meal 138 
(i.e., 400 mL of Ensure Plus®, equal to 700 calories). After aspiration of these fluids as a function of time, 139 
fluids were analyzed for pH and endogenous constituents (bile salts, phospholipids, cholesterol, enzyme 140 
activity and lipid digestion products). The results of this study demonstrated  wide variability in the presence 141 
of these constituents from person to person, although the study protocol was the same for each and every 142 
individual [18]. Especially for ionized compounds, the present pH in the intestinal tract is from paramount 143 
importance in order to dissolve and, subsequently, absorb. The research group of Prof. Amidon (University 144 
of Michigan) aspirated GI fluids from 37 healthy subjects after oral intake of an immediate-release 145 
ibuprofen tablet (800 mg) in fasted and fed state conditions [6,19]. Fluids were aspirated from different 146 
segments of the GI tract: stomach, duodenum and jejunum. This study demonstrated the highly fluctuating 147 
pH, especially in the duodenum, which was an important intrinsic factor besides motility explaining 148 
differences in systemic exposure of ibuprofen between and within subjects (Figure 1). 149 
 150 
 151 
 152 
 153 
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Figure 1: Mean pH versus time profiles in fasting (n = 20) and fed state (n = 17) conditions as measured in the stomach, the duodenum, and the 158 
jejunum (mean + SD). Figure depicted from Hens et al. 2017 [6]. Copyright ACS 2017. 159 
 160 
Besides solubility, absorption has always been a key parameter in estimation of drug performance. 161 
Multiple techniques are described in the literature to assess the intestinal permeability of drug compounds. 162 
The Loc-I-Gut® method, i.e., a double-balloon perfusion system, is an interesting study technique to explore 163 
the permeability for drug compounds in the different regions of the GI tract [20,21]. A specific region of 164 
the GI tract will be inflated by two balloons and thus separating a specific region of interest. Subsequently, 165 
a drug solution will be perfused and the amount of drug that will disappear is a measure for the amount of 166 
drug absorbed. The application of this technique has unraveled the intestinal permeability for 167 
hydrocortisone in the duodenum, jejunum and ileum. A recent review by Dahlgren et al. compiles historical 168 
Peff data from 273 individual measurements of 80 substances from 61 studies performed in all parts of the 169 
human intestinal tract [22]. This impressive data set has served as a reference for researchers in order to 170 
optimize the protocols of in vitro setups in order to improve the predictive performance of their in-house 171 
absorption tools [23]. 172 
With respect to the colonic physiology, recent findings, applying high-resolution manometry 173 
(HRM), have demonstrated that colonic motility is mainly represented by non-propagating and retrograde 174 
activity and both these activities increased soon after intake of a meal. These colonic motor patterns have 175 
the role of delaying the arrival of colonic content to the rectum and of favoring the retrograde filling of the 176 
transverse and ascending colon, where the propagating contractions normally start. Propagating 177 
contractions, including the high-amplitude propagating contractions associated with movements of solid 178 
colon content, represent a minority of the colonic activity and are normally more frequent about 1-2 hours 179 
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after the meal and upon awakening [24]. The reason of this is likely related to the fact that, in these moments 180 
of the day, the arrival of the content accumulated in the distal small bowel during the night and during the 181 
inter-digestive periods determine the distension of the ascending and transverse colon that trigger the 182 
propagating activity. The prevalence of non-propagating and retrograde activity explains the fact that the 183 
normal colonic transit time is slower (about 35 hours) as compared to the small bowel. This allows the 184 
colon to perform its functions of absorption, fermentation and to be an adequate reservoir organ. HRM is a 185 
useful technique to study colonic motor function but is invasive and normally requires a preparation of the 186 
bowel. This makes the technique less attractive when the colonic function needs to be studied under 187 
physiological conditions. Recently, other techniques have been applied to study the colonic function. The 188 
electromagnetic capsule is an ingestible silicone coated cylindrical magnet (21 mm by 8 mm) used to map 189 
the real-time movements of colonic contents. A plate containing a detection matrix of 4 x 4 magnetic field 190 
sensors is worn by an ambulatory patient around the abdomen to detect the movements of the pill. This 191 
matrix allows mapping of the pill movements in the x-, y-, and z-axis as well as the inclination angles 192 
applied by the colon.  The pill allows evaluation of the direction (anterograde and retrograde), velocity and 193 
length of movement of intraluminal content allowing the calculation of the colonic transit time. Recent 194 
studies have also demonstrated the first identification of colonic motor patterns consistent with those seen 195 
with HRM [25]. Moreover, MRI has also been introduced as it is able to measure both the colon free water 196 
content and the “fluidity” of the colonic content [26]. Recent animal studies have demonstrated that the 197 
colon is able to adapt to the physical characteristics of the intraluminal content and develops different motor 198 
response according to the presence of more or less fluid content [27]. It is highly likely that these 199 
physiological variables play a pivotal role in the dissolution and/or absorption of drugs that are triggered to 200 
be released at the colonic site in the human GI tract. 201 
Integration of GI Physiology Into a Predictive Dissolution Device: Where to Start? – Raimar 202 
Löbenberg, PhD 203 
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The GI tract is a complex and not well-understood sequence of organs with changing environments 204 
as a function of time. However, an in-depth mechanistic understanding of the obstacles and opportunities 205 
in each segment is necessary to achieve optimal drug absorption and bioavailability (BA) (Figure 2). 206 
 207 
Figure 2: An overview of the different GI physiological variables that can have a major impact on oral drug behavior in the GI tract. 208 
 209 
Figure 2 shows multiple factors impacting the fraction dose absorbed without considering 210 
metabolic or drug stability compromising degradation processes. The Biopharmaceutics Classification 211 
System (BCS), represented by the blue box, focuses on permeability and solubility [28]. However, drug 212 
dissolution and solubility depend on additional physiological factors that are summarized in the red box. 213 
Motility effects and gastric emptying are know to have an impact on the performance of a drug product but 214 
they are seldom considered in drug development. In contrast, food effects, pH effects and solubilization 215 
effects by bile salts were studied intensively in the past decades. However, today, there is still no consensus 216 
Oral drug absorption factor 
transit time 
gastric emptying 
Intestinal motility 
Peff 
Solubility (pH) 
food effect 
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on a universal dissolution media, which can be used in drug development and for in vitro performance 217 
testing to capture these effects. Early studies evaluated the solubility of glyburide, a BCS class II drug, in 218 
biorelevant media [29]. It was shown that the increased solubility in bile salt media (containing sodium 219 
taurocholate and egg-lecithin) was suitable to establish an in vivo-in vitro correlation (IVIVC) when 220 
computer simulations were applied. A linear regression was established in GastroPlus™. Applying a 221 
biorelevant solubility value resulted in a regression coefficient of 0.94 for the reference formulation.  The 222 
prediction error (%) regarding simulated plasma Cmax and AUC were7 and 14% , respectively, when using 223 
these biorelevant solubility value as an input in GastroPlus™. Solubility values obtained in aqueous media 224 
(pH 6.5) resulted in a 38 and 63% prediction error with respect to plasma Cmax and AUC.Later on, a dynamic 225 
dissolution protocol was developed in biorelevant media (i.e., FaSSIF) which again showed predictive 226 
power for establishing an IVIVC [30]. The dynamic dissolution protocol was then applied to a flow-through 227 
apparatus for montelukast sodium. Again, the biorelevant media gave the best fit to clinically observed data 228 
[31]. These early studies were successful to establish IVIVC without considering other GI factors. In a 229 
study by Almukainzi et al., the impact of gastric motility on the pharmacokinetics (PK) of meloxicam was 230 
studied [32]. It was observed that two formulations (conventional versus fast dissolving) had a similar PK 231 
pattern when administered in a rodent model. However, when the gastric motility was impaired the stomach 232 
controlled the drug release and therefore the drug absorption for the conventional dosage form. The PK of 233 
the fast dissolving formulation was close to the pattern observed in the healthy state. This study indicated 234 
that formulation differences, which are not relevant under healthy conditions, might result in significant 235 
differences under disease state. This study showed that the stomach in disease conditions is able to 236 
negatively impact PK parameters such as plasma Cmax and Tmax. Furthermore, it is well accepted that gastric 237 
emptying impacts the PK in fasted versus fed state for many drugs. However, less attention is given to the 238 
fact that GI motility impacts Cmax and Tmax depending on the dosing time and the MMC phase. This might 239 
be due to the fact that the PK models used to quantify and describe the PK behavior of drugs sooth-out 240 
individually observed variability in the mean PK profiles. However, if motility and PK are both monitored 241 
a relationship between observed plasma levels and intestinal motility are getting more obvious. Another 242 
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factor for alternations in drug absorption is the composition of the intestinal juices. The buffer system in 243 
the GI tract is carbonate-based. In routine pharmaceutical quality control (QC) and development, phosphate 244 
buffers play a major role while carbonate buffers are seldom used. The choice of phosphate over bicarbonate 245 
seems to impact the in vivo performance of enteric-coated dosage forms. Early reports show the failure of 246 
enteric-coated products in vivo (1964) and are confirmed over several decades until today by in vivo studies 247 
[33–35]. Also, there is evidence that phosphate and carbonate buffers seem to interact differently with the 248 
enteric-coated polymers. It is obvious that a re-evaluation of established in vitro testing is important to 249 
capture in vivo relevant performances to avoid product failure. The next important differences, besides 250 
buffer nature, are buffer strengths used in in vitro dissolution protocols versus the present buffer strength 251 
in the GI tract and the impact of the intestinal absorption on drug dissolution. Biphasic dissolution is known 252 
for many years as a surrogate to assess the the in vivo performance of a drug formulation [36]. Based on 253 
the permeated amount of drug appearing in the organic layer, estimations related to the fraction absorbed 254 
can be performed [37]. However, its impact on IVIVC has not yet been fully appreciated. In a recent study, 255 
we investigated the dissolution behavior of ibuprofen in pharmacopeial and GI equivalent phosphate buffer 256 
strength. The results showed that ibuprofen dissolved fully under the pharmacopeial conditions in less than 257 
15 min. However, at low buffer strengths, this process took much longer, and the pH of the media changed 258 
significantly due to the acetic nature of ibuprofen. However, if a biphasic dissolution test was performed, 259 
the pH recovered over time close to the original value. This again demonstrates how important 260 
physiologically adapted in vitro testing can be to capture what happens in vivo. Only this can ensure that in 261 
vitro methods are predictive of in vivo performance. The translation of such methods into QC methods 262 
needs to be investigated in the future in more detail. The last aspect deals with the irrelevance of in vitro 263 
behavior on the drug product performance in vivo. An example of such rare case is dextromethorphan [38]. 264 
This drug is absorbed to over 80% in 2 hours but it takes about 15-20 hours to observe the maximum 265 
fraction dose absorbed. A classical IVIVC would correlate fraction dose absorbed versus the dose dissolved. 266 
However, in this specific case, the IVIVC would be misleading. The drug dissolves fast in the gut and is 267 
completely dissolved within 15 min. As mentioned before, >80% will be absorbed into the enterocytes 268 
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within 2 hours. The drug undergoes lysosomal trapping after entering the enterocyte. As a weak base, it is 269 
highly lipophilic at physiological pH in the cytoplasm. As the drug will migrate through the enterocytes 270 
from the apical to the basolateral side, it can pass through the membranes of the lysosomes and it can enter 271 
into an aqueous environment with a slightly acidic pH. In this organel, the weak base becomes more 272 
hydrophilic and, therefore, will be entrapped in the lysosomes. That isis why it takes more time to appear 273 
in the blood than it takes time to be absorbed. Such drugs dissolution tests are not useful surrogates for in 274 
vivo performance since the dissolution of the drug product cannot be directly correlated to the plasma levels. 275 
It is the biological system and its specific environments and drug partition between the cell compartments, 276 
that determine the appearance of the drug in the central compartment and not the drug dissolution. In 277 
summary, GI drug absorption is highly impacted by different physiological factors. In vitro performance 278 
testing should consider and include physiologically-adapted test protocols to identify potential clinical 279 
relevant dosage form factors. A BCS sub-classification system, which includes acids, bases and neutral 280 
molecules can help to identify potential obstacles for oral drug absorption for these different groups [39]. 281 
To meet all these standards, a potential in vitro apparatus, which can simulate the different GI conditions, 282 
is shown in Figure 3.  283 
 284 
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  285 
 286 
Figure 3: Illustrative presentation of an in vitro dissolution model taking into account the different physiological barriers of the GI tract that may 287 
have a major impact on drug’s dissolution and absorption. 288 
In Vitro Dissolution for a Marketed and Generic FDC Drug Product: Bioequivalent or not? – 289 
Marival Bermejo, PhD 290 
Development of Fixed-Dose Drug Combination (FDC) products could be challenging when both 291 
drugs do not belong to the same BCS class i.e., when the limiting factors for their absorption are different. 292 
In the first part of the presentation, the relevance of exploring the biopharmaceutical properties of each drug 293 
in the combination product were discussed in the framework of different classification systems. The BCS 294 
system has evolved from a regulatory conservative classification framework in which the main concern is 295 
to ascertain the non-bioequivalence (non-BE) risk to a development tool which can help on the formulation 296 
strategy selection [40,41]. In order to understand the biopharmaceutical limiting factors for a given drug 297 
the cut-offs and methods for permeability and solubility estimation of BCS are modified in the 298 
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developability classification system (DCS). The DCS considers a higher available fluid volume (500 mL) 299 
in the small intestine and the solubility in human intestinal fluids for solubility classification. The volume 300 
of 500 mL is calculated based on the co-administered fluid and present residual fluid along the GI tract 301 
[40].Another relevant addition is the differentiation between solubility-limited and dissolution-limited 302 
drugs as the formulation approaches may differ. The selection of the dissolution test to explore the risk of 303 
the non-equivalence outcome in vivo can be made based on the drug physicochemical characteristics. For 304 
that purpose, a sub-classification system from BCS was proposed by Tsume et al. [39]. BCS class II drugs 305 
were sub-classified in neutral (BCS IIc), weak acids (BCS IIa) and weak bases (BCS IIb). Following these 306 
sub-divisions, the suggested dissolution tests to forecast in vivo behavior differ from class I and III for 307 
which simple dissolution apparatus (as USP II) could suffice and from class II and IV for which a gastric 308 
compartment and an absorptive sink should be included in order to increase the in vivo predictability. To 309 
accommodate that need, several dissolution system have been proposed in the literature and as example 310 
several transfer systems and two-phase or biphasic dissolution systems were described [37,42–47]. In the 311 
second part of the lecture, the potential effects of formulation excipients were discussed in as well as 312 
experimental preclinical models to study those effects. Excipients can affect membrane permeability and 313 
metabolism and GI motility either at gastric emptying level or at intestinal level. In Table 1, some 314 
experimental methods with useful references are summarized. 315 
 316 
 317 
 318 
 319 
 320 
 321 
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Table 1: Overview of potential in vitro/in situ methods to apply in order to explore a physiological variable of interest. 322 
Effect Model Reference (PMID) 
Intestinal 
permeability 
Caco-2; In situ perfusion (Rat –Mouse) [48–52] 
Intestinal 
metabolism 
In situ perfusion in addition to mesenteric vein 
canulation 
[48,53,54] 
Gastric 
emptying 
Charcoal suspension Rat; Phenol red + 
Loperamide; Barium suspension 
[55–57] 
Intestinal 
motility 
Charcoal suspension Rat [55] 
 323 
For instance, the effect of sodium lauryl sulfate (SLS) on the intestinal permeability of fexofenadine 324 
was characterized with Doluisio’s closed-loop perfusion method and further evidenced by in vivo BA 325 
studies in rats [58,59], while the relevance of gastric emptying changes due to excipients as the reason for 326 
a failed bioequivalence study was assessed with a barium sulfate gastric emptying test in rats [60]. Finally, 327 
the concept of using BCS as a risk assessment tool of bioequivalence(BE) issues was with the aid of a case 328 
study of an FDC development. A valsartan/hydrochlorothiazide generic product failed twice the BE test in 329 
each one failing for one of the drugs while succeeding for the other one. The application of a biopredictive 330 
dissolution test using the Gastrointestinal Simulator (GIS) was successful in reproducing the in vivo 331 
outcome as differences in disintegration in the stomach chamber and differences in dissolution rate on the 332 
intestinal compartments were the apparent reasons for the in vivo failure due to different levels of sorbitol 333 
and SLS on the generic formulations. To conclude, BCS and/or DCS classification of drugs in an FDC is a 334 
tool to define the absorption limiting factors and the relevant physiological variables affecting BA. For 335 
FDC with drugs belonging to different BCS classes a combination in vitro dissolution methods and 336 
preclinical models is necessary to assess formulation performance.  337 
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Challenges and Opportunities to Grant BCS and Dose Strength Based Biowaivers for FDC 338 
Products – Pablo M. González, PhD 339 
FDC products combine two or more active pharmaceutical ingredients (API) in a finished 340 
pharmaceutical dosage form at a fixed ratio of doses [61]. FDC products are approved based on the 341 
combination rule that states that each component should contribute to product effectiveness and that the 342 
combination should also be safe in a particular patient population [62,63]. Safety and efficacy data can be 343 
totally (New Drug Application) or partially (505(b)(2)) original or based on previous reports (Abbreviated 344 
New Drug Application) [64]. FDC products offer several advantages over co-administration of the single 345 
entity product (SEP) such as greatest patient compliance, increased safety and efficacy, minimized abuse 346 
potential, and reduced cost for patients. They also offer opportunities for manufacturers to extend 347 
intellectual property and exclusivity along product life-cycle [65]. On the other hand, formulating FDC 348 
products impose several challenges related to incompatibility between APIs and incompatible interactions 349 
with certain excipients. Some drugs might degrade in presence of another (amiodaquine HCL-artesunate), 350 
others might be pharmaceutically incompatible (simvastatin-telmisartan) [66], some drugs could display 351 
very different viscoelastic properties (metformin-glibenclamide), and others might interact at the absorptive 352 
(e.g.., intestinal transporters) or post-absorptive (e.g., metabolic enzymes, renal transporters) level. 353 
WHO classifies FDC products into 4 different scenarios regarding regulatory requirements for product 354 
registration: 355 
 Scenario I: The new FDC product has the same APIs and doses as an existing FDC product 356 
 Scenario II: The new FDC product has same APIs and doses as an established regimen of single 357 
entity products (SEP) 358 
 Scenario III:  359 
o a) The new FDC product combines APIs with established safety and efficacy data but that 360 
have not been used in combination for that particular indication 361 
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o b) The new FDC product comprises a combination of APIs with established safety and 362 
efficacy but will be used in a different dosage regimen 363 
 Scenario IV: The new FDC product contains one or more new chemical entity (NCE) 364 
BE studies are required in order to bridge pivotal clinical data of the reference listed drug (RLD) 365 
product(s) to safety and efficacy of FDC products belonging to Scenarios I and II. While the design of BE 366 
study for scenario I is standard, in scenario II the in vivo performance (e.g., PK end-points) of the FDC 367 
product is compared to the co-administration of the SEPs. In both cases, successful BE indicates the absence 368 
of (or similar) PK interactions between APIs. However, BE studies for FDC products are challenging due 369 
to: i) potential changes in PK intra-subject variability in the combination product; ii) non-linear PK in a line 370 
of strengths; iii) drug-formulation interactions; and iv) differential impact of food on API PK when 371 
administered as a combination product [67]. These considerations make biowaivers a highly attractive 372 
opportunity for manufacturers to fulfill the BE requirement. Currently, WHO, the Food and Drug 373 
Administration (FDA), the European Medicines Agency (EMA), the International Conference on 374 
Harmonisation (ICH), and Health Canada allow BCS-based biowaivers for immediate release (IR) FDC 375 
products containing high-solubility APIs only [68–70]. Thus, FDC products containing BCS class I and/or 376 
III APIs could apply for a biowaiver. In general, dissolution, and compositional requirements are the same 377 
as those for SEP, with some differences among jurisdictions. For BCS class I API FDA requires the use of 378 
excipients present in currently FDA-approved IR products, while EMA encourages the use of similar 379 
amounts of the same excipients as the reference product. The 2018 ICH Guidance on BCS-based biowaivers 380 
states that critical excipients (e.g., polysorbate 80, sorbitol) must be within ± 10% of reference product. On 381 
the other hand, there is a consensus among jurisdictions regarding the impact excipients might have on BCS 382 
class III drugs, such that agencies require excipients to be qualitatively (Q1) the same and quantitatively 383 
(Q2) very similar to the reference product. FDA and ICH guidances contain tables with allowable 384 
compositional differences of excipients (by function) relative to the reference product. The implementation 385 
of a BCS-based biowaiver for a scenario I-type FDC product is straight forward provided products are 386 
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pharmaceutically equivalents and dissolution and compositional requirements are fulfilled. Additionally, 387 
FDA might accept BCS-based biowaivers for pharmaceutical alternatives if appropriately justified. On the 388 
other hand, a BCS-based biowaiver for scenario II-type FDC products impose some challenges for both 389 
manufacturers and regulatory agencies. First, different single-entity RLD products might be registered in 390 
different regions, implying that a manufacturer would have to perform multiple biowaiver studies if 391 
pursuing approval in various jurisdictions. This can be further complicated by the fact that unlike FDA, 392 
EMA does not publish a list with RLD for different European countries. Second, FDC containing 393 
incompatible APIs need to incorporate a segregation technology (e.g., bilayer tables, tablet-in-tablet, etc.) 394 
in order to obtain a stable product. In this case, it might be difficult to account for the compositional 395 
requirement between the FDC product and the respective SEP. Third, dissolution methods to study FDC 396 
products with large dose disparity between APIs (i.e., dose ratio > 50) might be analytically challenging. 397 
This could be further complicated in cases where APIs display divergent pH-dependent stability in the 398 
physiological range. Furthermore, RLD SEPs might use different dissolution apparatus (e.g., basket or 399 
paddle) such that manufacturer might have to develop and validate two dissolution methods for one FDC 400 
product. Fourth, there is a chance for pre-absorptive PK drug-drug or drug-formulation interactions (DFI) 401 
in FDC products that could be either different or absent when the SEPs are co-administered. Both FDA and 402 
EMA have published guidelines regarding studying drug-drug interactions (DDI) at the transporter level 403 
[71,72]. FDA has also published methodological recommendations to study in vitro transporter-mediated 404 
DDI [71]. While agencies require sponsors to study intestinal efflux transporter-mediated DDI (i.e., P-405 
glycoprotein, breast cancer resistance protein), there is currently no published recommendation on studying 406 
potential DDI mediated by intestinal uptake transporters. This seems surprising since it is well recognized 407 
that intestinally expressed uptake transporters interact with a vast number of drugs belonging to structurally 408 
diverse chemical and therapeutic classes [73]. Moreover, there is growing evidence that pharmaceutical 409 
excipients can inhibit both efflux and uptake intestinal transporters in vitro and in situ. Documented 410 
examples include PEG-ylated surfactants, sorbitan fatty acid esters, and polyethylene glycol [74–76]. While 411 
there is a consensus that DDI or DFI might be of minor clinical relevance for BCS class I drugs, there also 412 
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a concern that these interactions could greatly impact the oral absorption of low permeability APIs. FDC 413 
products also offer opportunities for developing a line of strengths that can be used to optimize therapy by 414 
dose titration. Intermediate and low strengths could apply for a dose strength (DS)-based biowaiver 415 
provided there is at least one strength (typically the highest) that successfully demonstrated BE to the 416 
reference product in vivo. Dose strength-based biowaivers are applicable to APIs that are not eligible for 417 
BCS-based biowaivers and to pharmaceutical forms other than IR (i.e., modified-release, delayed-release). 418 
Common requirements for DS-based biowaivers among jurisdictions are linear PK in the therapeutic dose 419 
range, with a chance for bracketing approach between the highest and the lowest strength, and same 420 
manufacturing process for the strength line [77]. The dose range for a FDC will be dependent on the additive 421 
or synergistic effect of the investigational drugs. The interaction between the drugs are assessed in drug-422 
drug interaction and PK-PD studies. Subsequently, exposure-response models can be used for Phase 2B 423 
dose selection [78]. As in the case of BCS-based biowaivers, DS-based biowaiver requirements are an 424 
extension of those for SEPs. Tables 2 and 3 summarize FDA and EMA compositional requirements and 425 
dissolution method recommendations for DS-based biowaivers. Data presented in Tables 2 and 3 imply that 426 
manufacturers pursuing a DS-based biowaivers in the US and European market might face challenges 427 
fulfilling compositional requirements for FDC products based on segregation technologies (e.g., bi-layer 428 
tablets) since EMA treats each layer as a separate entity while FDA considers bi-layer tablets as a single 429 
unit. Also, in the case of single unit FDC products with large dose disparity between APIs it might be very 430 
difficult to fulfill proportionality requirements by both FDA and EMA. More specifically, EMA states that 431 
in order to calculate API/excipients proportionality the other API must be considered an excipient. 432 
However, it is not clear whether the other API must be considered as a filler for proportionality calculations. 433 
Similarly, there is no specific FDA recommendation as to how to consider the other API in bi-layer tables. 434 
These discrepancies can hinder simultaneous registration of an FDC product in both USA and Europe. 435 
Additionally, while FDA requires bioequivalence studies for the highest dose in the strength line, EMA 436 
requires studies at the lowest strength in addition to the highest strength. Finally, the existence of different 437 
 20 
 
reference products among jurisdictions increases the number of studies a sponsor needs to execute if seeking 438 
approval in various regions.  439 
 440 
Table 2: Comparative compositional requirements to grant dose strength-based biowaivers by FDA and EMA*. 441 
Criteria FDA EMA 
General 
composition 
All ingredients and APIs are in the 
same proportion between diff. 
strengths 
Q1 the same and Q2 proportional across 
different strengths 
High-potency APIs 
 Total weight nearly constant across 
strengths (±10% from bio-batch) 
 Q1the same across strengths 
 Only APIs vary across strengths, and 
one or more excps. 
 Amount of API <5% core weight or 
capsule filling 
 Amount of excps. constant only API 
varies 
 Only filler changes to account for 
changes in APIs 
ANDA 
Proportion between API and excps. 
might vary across strengths if same 
BA is achieved 
No special considerations 
Bi-layer tablets 
Bi-layer tablets are considered as a 
single unit 
Each layer is considered independently 
Prolonged Release 
 Beaded capsules: only number of 
beads varies across strengths 
 Single unit products similar general 
requirements 
 Multiple unit formulation: BEq for the 
highest strength 
 Single unit formulation: bracketing 
approach 
 Release-controlling (or coating) excps. 
must be the same for the line of 
strengths. 
FDC Not discussed 
 Proportionality requirements must be 
fulfilled for all APIs 
 The other APIs must be considered an 
excp., except in bi-layer tablets 
*Adapted from [77]. 442 
 443 
 444 
 445 
 446 
 447 
 448 
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Table 3: Dissolution method recommendations by FDA and EMA for dose strength-based biowaivers*. 449 
Criteria FDA EMA 
IR products 
 
i) Compendial method 
ii) FDA recommended /USP general 
chapter 
iii) Develop new method using diff. 
agitation speeds, pH (1.2, 4.5, 6.8). 
Water can be used. Add 
surfactants if API is poorly soluble 
 
i) pH (1.2, 4.5, 6.8) and QC method 
ii) If sink condition cannot be achieved 
at a particular pH for all strengths, 
compare to dissolution profile of 
RLD at same dose or using multiple 
units of lower strengths 
 
MR products 
 
 If no compendial method submit ii) 
+ pH (1.2, 4.5, 6.8) for comparisons 
 Select the most discriminating 
conditions (agitation, media) based 
on in vitro and in vivo data 
*Adapted from reference [77]. 450 
 451 
Considering the Biopharmaceutics and Physicochemical Aspects of FDC – Amitava Mitra, PhD 452 
Amitava Mitra, Ph.D. (Sandoz, Inc, A Novartis Division) discussed the key challenges and strategies to 453 
overcome such challenges, in achieving BE for FDC products containing two or more of active ingredients 454 
[67]. The active ingredients of these products may work through different pharmacological pathways and 455 
offer advantages of additive/synergistic effect, reduced dose of each active, and improved patient 456 
compliance. Novel FDCs of Parkinson’s drug, Levodopa, are an example of efforts to improve the clinical 457 
outcome of an old drug using new technologies and mechanisms to improve patient function [79]. However, 458 
combining multiple active ingredients may complicate their individual biopharmaceutic and PK behavior. 459 
The development of controlled or modified release FDC products does add additional challenges due to 460 
changes to the drug release profiles. Such changes in the release profile can change the biopharmaceutic 461 
and pharmacokinetic profiles of the API. Interested readers should review the following published 462 
references [67,80–82]. The importance of critically reviewing the physicochemical and biopharmaceutics 463 
properties and their impact on PK of the individual drugs being considered for the FDC was also discussed. 464 
Gaining a thorough understanding of the PK properties of the individual drugs along with the formulation 465 
variables being considered for the FDC is an equally important consideration. Pilot BA studies designed 466 
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to answer the most pertinent questions relating to the FDC strategy are important and encouraged. 467 
However, underpowered studies with too many variables can further confound an already complex issue 468 
and should be avoided. Pivotal BE studies should be designed with due consideration of all the 469 
physicochemical, biopharmaceutic, and PK data for the compound from all sources. BE study designs 470 
specific to highly variable drugs such as scaled BE or cross-over replicate designs may be considered. 471 
Leveraging the knowledge gained from varying but synergistic techniques such as in vitro 472 
solubility/dissolution studies, in silico absorption models and IVIVC's, in vivo preclinical animal models, 473 
and the available in vivo clinical data is paramount to the success of the FDC strategy for a given 474 
combination. Two case studies were discussed where the use of oral absorption modeling, dissolution data 475 
and clinical PK data were used to successfully develop FDC products. In the first case study, the 476 
development of a triple combination product was discussed, where one of the active ingredients had a 477 
highly variable Cmax and another active had a long Tmax due to bile secretion and slow absorption. In this 478 
case oral absorption modeling was key to understanding the impact of formulation changes on PK of the 479 
three actives and ultimately in development of the FDC product. In the second case study, the development 480 
of a double combination product was discussed, where one of the active ingredients was a weak base with 481 
high intra-subject CV and steep pH-solubility profile. In this case, data from several relative BA studies 482 
and a thorough understanding of the PK and biopharmaceutic properties helped with the successful 483 
development of the FDC.  484 
Current Regulatory Requirements to Assess Bioequivalence of FDC Products Worldwide 485 
(EU/USA/ Latin America/Japan) – Alexis Aceituno, PhD 486 
Although one of the purposes is to combine drugs at fixed dose ratios to simplify treatment of 487 
chronic diseases and improve patient adherence, there is a general consensus that this rationale cannot be 488 
the only goal behind any development or formulation design [83]. An overview regarding regulations for 489 
filing FDC products throughout various jurisdictions around the world shows that progress on this matter 490 
has been rather slow. Overall, the development of FDC products by combining previously approved mono-491 
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products or starting from the co-formulation of NCEs can follow limited regulatory pathways. Under US 492 
regulations the FDCs regulatory fundamentals are described in the Code of Federal Regulations and 493 
guidelines that outline the requirements for FDC product approval. The introduction of co-development 494 
guidance in 2013 reflects the importance of these pharmaceutical products from a regulatory perspective 495 
[62]. The guidances describe that drug product efficacy can rely on BE testing if there is no change in 496 
dosing or proposed therapeutic indication for a novel FDC or clinical data are required otherwise. FDC 497 
products could follow one of the following regulatory pathways: 505 b(1), 505 b(2) or 505 j covering all 498 
the possibilities from new development to generic development. On the other hand, EMA launched several 499 
guidelines with respect to the clinical development of FDC products reflecting the proposed therapeutic 500 
used and indications of any FDC development [63]. The guidance describes three possible situations with 501 
specific requirements for demonstrations of efficacy: 1) the use of an FDC product as add-on treatment if 502 
there is a deficient response to one or more drugs to be included in the proposed combination. Drug-Drug 503 
(DDI) or PK interaction study may be required if the combination poses a threat with potential clinical 504 
consequences; 2) substitution by an FDC product when a reduction of pill burden is sought after. 505 
Bioequivalence testing is required and special attention should be paid if the FDC product is dosed at 506 
different time intervals, and 3) FDC therapy initiation if the FDC product has not been used previously for 507 
any particular indication. Both clinical and pk trial, as well as DDI study, should be performed and 508 
submitted prior to approval. In Latin America, there is only one specific guidance for registration of FDC 509 
products since 2010 [84]. It describes the definition of FDC products, general consideration for filing and 510 
regulatory requirements that depend on the proposed dose scheme or the drugs to be combined. FDC 511 
approval can be granted under the following conditions: 1) An FDC product contains the same actives, dose 512 
and dose regimes as mono products used concomitantly, therefore the safety and efficacy profiles are well 513 
known; to demonstrate efficacy, a bioequivalence study may be sufficient; 2) same conditions as in “1”, 514 
but FDC product is going to be used in novel dose or new therapeutic indication and therefore a phase III 515 
clinical trial is required; 3) the combination contains one or more new active ingredients and phase I, II and 516 
III clinical trials are required to gain approval. In general, there is not a globally applicable guideline for 517 
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FDC product registration, but for specific therapeutic classes and four general cases that are described in a 518 
WHO technical report, aiming at guiding pharmaceutical companies for development, approval, and 519 
marketing FDC products under less developed jurisdictions [61]. Although generic and hybrid submission 520 
pathways seem to be sufficient under most jurisdictions, preclinical and clinical data for novel combinations 521 
will always be needed if individual components in FDC products are either known or they are new 522 
investigational drugs. However, the idea still persists among regulated entities that different jurisdictions 523 
around the world should give more importance to convenience/compliance as a rationale for developing 524 
FDC products either containing authorized/new drug entities or authorized drugs only bearing in mind 525 
patient´s satisfaction or reduced/contained health costs [85]. If generic development is allowed, a BE study 526 
design for a FDC product should consider the same principles as if the drugs were given alone, looking for 527 
the achievement of equivalence in PK profiles for each FDC active ingredient and their respective either 528 
reference FDC or reference mono products. At this point, it is important to realize that PK interactions may 529 
have more critical consequences with FDC products than the same drugs given as mono products 530 
concomitantly. To conclude, when comparing jurisdictions to obtain FDC product approval, it seems 531 
necessary that a balance should be reached between an overcautious registration approach and the potential 532 
large public health benefits that would arise from affordable FDC products of proved efficacy. The 533 
achievement of broad harmonization in the understanding and application of existent technical guidelines 534 
and requirements for FDC product development and registration is still a pending matter.  535 
Formulation Design, Challenges, and Development Considerations for Fixed Dose Combination 536 
(FDC) of Oral Solid Dosage Forms – Divyakant Desai, PhD 537 
For formulation scientists without prior experience of the FDC development, two decision trees 538 
were discussed to select the most suitable formulation development strategy. The first decision tree was 539 
related to the formulation design for an FDC product (Figure 4).  540 
 541 
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 547 
Figure 4: Decision tree for the formulation design of a FDC. Figure adopted from Desai and colleagues [86]. Copyright Taylor and Francis 548 
2013. 549 
 550 
 551 
 552 
 553 
 554 
 555 
If two drugs are chemically incompatible, multi-layer tablet or a drug-specific multi-particulate 556 
system was proposed. If they are compatible, then a monolithic system was proposed unless there is a need 557 
to keep them apart in order to maintain the dissolution profiles comparable to the respective single entity 558 
product. The second decision tree was about the selection of the manufacturing process for an FDC product 559 
(Figure 5). 560 
 561 
 562 
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 567 
Figure 5: Decision tree for the manufacturing process selection of a FDC. Figure adopted from Desai and colleagues [86]. Copyright Taylor 568 
and Francis 2013. 569 
 570 
 571 
 572 
 573 
 574 
 575 
The drug loading in the formulation dictated the selection of the manufacturing process. If the drug 576 
loading is high, a hot melt extrusion (HME) or a bi-layer method of manufacturing was proposed. For a 577 
formulation with a low drug loading, an active coating approach was proposed. One of the crucial factors 578 
in the manufacturing process selection is a pharmaceutical scientist prior experience with the manufacturing 579 
process under consideration. A monolithic formulation system, where two drugs are incorporated in a single 580 
dose unit, is considered the most simple formulation approach. However, a case study was presented where 581 
a second drug, hydrochlorothiazide (HCTZ), was added to the existing formulation of a hypertensive drug 582 
[87]. It was shown that povidone (a binder) and poloxamer (a wetting agent) triggered HCTZ degradation 583 
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under accelerated storage conditions by solubilizing HCTZ in available moisture. Replacement of povidone 584 
by Starch 1500, resolved the stability issue and removal of poloxamer did not impact the BE study 585 
adversely. For a bi-layer tablet formulation approach, which is normally used to keep two incompatible 586 
drugs apart or to maintain two drug release profiles, few critical formulation factors were presented. Those 587 
factors include the selection of excipient with high fragmentation tendency such as lactose in the first layer, 588 
more deformable material such as microcrystalline cellulose in the second layer, the weight ratio of not 589 
more than 1:6 for two layers. It was also emphasized that the tamping force for the first layer should be able 590 
to reduce the volume without sacrificing the surface roughness which is essential for the adhesion of the 591 
second layer. Two case studies were presented on the bi-layer formulation approach. In the first case study, 592 
the compressibility of an extended release metformin formulation was improved by the addition of 1% w/w 593 
silicon dioxide. In the second case study, two different grades of fumed silica behaved differently in a bi-594 
layer tablet formulation [88]. Aerosil 200 did not cause layer separation but Aeroperl 300 did. Aeroperl can 595 
adsorb relatively large amounts of moisture at any humidity level due to its greater surface area, but it does 596 
not retain moisture when the humidity decreases. In contrast, Aerosil adsorbs relatively smaller amounts of 597 
moisture but it retains moisture due to its large pore sizes.  It was hypothesized that the moisture not retained 598 
by Aeroperl could be available for interactions with other layer excipients such crospovidone. The third 599 
formulation technique presented was an active coating technology. An active coating can also be used to 600 
maintain two separate release profiles and to separate two incompatible drugs. A case study was presented 601 
to show how acid and base sensitive molecule was stabilized selecting and minimizing the excipients in a 602 
coating material API come in intimate contact with. For example, 1 mg drug is placed with 99 mg of 603 
excipients for a 100 mg tablet, the 1 mg drug can react with 99 mg of excipients. However, if 1 mg drug is 604 
placed with 9 mg of coating material, the amount of available for a reaction is reduced drastically. It is also 605 
a useful technology to make a tablet for a compression sensitive molecule. Although the active coating is 606 
useful, it is not as widely used as other technologies because it presents two big challenges. The first 607 
challenge is how to detect coating endpoint so that tablets with correct potencies can be manufactured. If a 608 
coating process is stopped early, tablets may be sub-potent.  On the other hand, if the coating is stopped 609 
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late, tablets may be super potent. The second challenge is content uniformity (active coat uniformity). The 610 
content uniformity can be influenced by various process parameters such as pan load, coating time, number 611 
of coating guns, and spray quality. A mathematical model was presented in which model parameters were 612 
linked with the process parameters for scale-up. It was shown that the model correctly predicted coating 613 
uniformity of tablet weighing 200 mg to 1450 mg in different shapes at a 450 kg commercial scale. In 614 
summary, the decision trees are very useful to explore the most suitable formulation and manufacturing 615 
process for an FDC formulation. Each formulation approach for an FDC will have its own unique challenges 616 
but as illustrated by various case studies, it is possible to overcome these challenges to develop a rugged 617 
formulation and a commercially viable manufacturing process using various process analytical technologies 618 
(PAT).  619 
Clinical Pharmacology Aspects of Fixed-Dose Combination Drug Development – Dakshina Murthy 620 
Chilukuri, PhD 621 
 Combination products are defined in the Code of Federal Regulations [21 CFR 3.2 (e)]as categories 622 
of drug-drug combination products. These products could be two or more approved drugs or investigational 623 
drug(s) developed along with an approved drug(s) or two or more investigational drugs developed together. 624 
The final products can be FDCs, co-packaged products or separate individual products administered 625 
together. Among the reasons why these products are developed are the additive/synergistic effects of drugs 626 
for the same disease (e.g., anti-viral and cough/cold drug products). Sometimes when two drugs have 627 
complementary mechanisms of action they are developed for the same disease as an FDC product. For 628 
instance, combining a beta-lactam with a beta-lactamase inhibitor allows for selective killing of bacteria 629 
that would otherwise be resistant to the beta-lactam. There are examples of FDCs where one component is 630 
included to reduce the adverse events of the other component (e.g. naproxen/esomeprazole delayed-release 631 
tablets). Most FDCs are oral but there are examples of inhalational (e.g., tiotropium/olodaterol for Chronic 632 
Obstructive Pulmonary Disease, (COPD)) and ophthalmic products (e.g., netarsudil/latanoprost for 633 
lowering intraocular pressure). The purpose of this presentation was to provide an overview of the clinical 634 
pharmacology considerations in FDC development. FDC development offers interesting challenges to drug 635 
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developers. If two or more new molecular entities (NMEs) are being developed as an FDC then dose-636 
finding studies of the drugs are generally required to determine the appropriate dose of each drug to be 637 
combined. If the FDC product contains drug component(s) not included in an approved combination 638 
therapy, then a factorial design clinical efficacy/safety study may be required to demonstrate the 639 
contribution of each drug component. Drug administration challenges such as the effect of food on the FDC 640 
will generally need to be addressed. This scenario could get more complicated when the various drugs 641 
proposed in the FDCs have different requirements for administration under fed and fasted conditions or 642 
when the drugs have different dosing frequency. These scenarios generally require a closer look at the FDC 643 
formulation and potential for additional BA studies. Dose adjustments of FDCs in specific populations are 644 
potentially problematic given the formulation inflexibility. The typical study conducted as part of the 645 
development program of an FDC is a relative BA study. The purpose of the BA study of an FDC is to 646 
compare the rate and extent of absorption of each active drug ingredient or therapeutic moiety in the FDC 647 
to the rate and extent of absorption of each active drug ingredient or therapeutic moiety administered 648 
concurrently as separate, single-ingredient preparations [21 CFR 320.25(g)]. Generally, a two-treatment, 649 
single-dose, fasting study of the FDC versus single-ingredient drug products at the highest strength of the 650 
combination product with matching doses of individual drug products is recommended [89]. Alternative 651 
study designs such as a three-treatment study design comparing the combination drug product versus single-652 
ingredient drug products administered separately may be appropriate. A single-dose, food-effect study on 653 
the FDC is usually conducted to evaluate the effect of food on the FDC. Case studies related to BA studies 654 
conducted to support approval of FDCs were presented along with examples of FDCs approved based on 655 
factorial design studies for the FDCs in comparison versus the individual components administered 656 
separately. The FDA guidance entitled “Codevelopment of Two or More New Investigational Drugs for 657 
Use in Combination” lays out the scenarios where a factorial design study may be appropriate to establish 658 
the contribution of the individual components in the FDC. 659 
Concluding Remarks and Future Perspectives 660 
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Market access for FDC products is challenging in terms of achieving bioequivalence to co-661 
administration of the individual mono-products, but also because of formulation challenges (compatibility 662 
of API’s, doses). However, we should not neglect the impact of GI physiology on oral drug behavior which 663 
can result in intersubject differences in systemic outcome, potentially leading to failures in bioequivalence 664 
studies. Therefore, it’s important to finalize a clear link between formulation strategy and clinical 665 
evaluation, supported by guidelines of regulatory authorities. In addition, the contribution of in vitro 666 
predictive dissolution testing can help assist regulatory decisions with respect to the approval of FDC 667 
products in a sense that these models identify the underlying GI variables playing a crucial role in the 668 
absorption process inside the GI tract. From an academic point of view, these clinically-relevant dissolution 669 
models can be optimized and validated when pharmaceutical companies would share their non-BE 670 
formulations (i.e., clinical failures). When they do so, the underlying problems can be unraveled which will 671 
be taken into account by formulations scientists when formulating FDC products.   672 
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